Despite skepticism from experts, Conceivable has raised $20 million in venture capital and is planning to launch another clinical study in Mexico City in September. In the long term, the company plans to run independent labs in partnership with OBGYNs. If all goes to plan, Conceivable could be running labs as soon as 2025.
Key takeaways:
- A startup called Conceivable Life Sciences is automating the in-vitro fertilization (IVF) process using robots and artificial intelligence (AI).
- The company has already achieved several breakthroughs, including being the first to robotically perform intracytoplasmic sperm injection (ICSI), a delicate process by which a sperm is placed inside an egg.
- Conceivable, which has raised $20 million in venture capital, aims to make IVF more affordable and efficient by automating the process, potentially saving patients tens of thousands of dollars.
- The company plans to launch another clinical study in Mexico City in September, enrolling 250 patients to test the full ensemble of its automated IVF process.